<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458835</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/M1-422</org_study_id>
    <nct_id>NCT00458835</nct_id>
  </id_info>
  <brief_title>Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™
      (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide
      HFA-metered-dose inhaler (MDI). The administration of the study medication will be as
      follows: three single doses, separated by a wash-out period. The study will provide further
      data on the safety and tolerability of ciclesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the systemic exposure to des-ciclesonide with OMNARIS™ (ciclesonide nasal spray), and ciclesonide HFA nasal aerosol and orally inhaled ciclesonide.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, safety and tolerability of ciclesonide will also be assessed.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Written informed consent and HIPAA

          -  Body weight as indicate by a Body Mass Index (BMI) between ≥ 18 and ≤ 28 kg/m², and a
             body weight &gt;50 kg

          -  General good health

          -  Ability to use oral inhaler

        Main Exclusion Criteria:

          -  Pregnancy, breast feeding, intention to become pregnant during the course of the study
             or lack of safe contraception in pre-menopausal women

          -  Participation in any investigational drug trial within the 30 days before Screening
             Visit and thereafter

          -  History or current clinically relevant allergies or idiosyncrasy to drugs or food

          -  History of allergic reactions to any corticosteroids including ciclesonide or any
             excipients of the formulations

          -  Any contraindication to nasally administered corticosteroids

          -  History of a respiratory infection or disorder [including, but not limited to
             bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory
             syndrome (SARS)] within the 30 days before Screening Visit, or development of a
             respiratory infection during the Screening Period

          -  History or current evidence of any other relevant allergic, cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological,
             psychiatric, or other disease within the last 2 years

          -  Non-vaccinated exposure to or active infection with, chickenpox or measles within the
             21 days preceding Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2007</study_first_submitted>
  <study_first_submitted_qc>April 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

